drugset / Trial / NCT01964989

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

NCT01964989

Phase 3 Completed 10644 enrolled Seqirus Novartis Vaccines · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.

Timeline

Start
2013-11
Primary completion
2015-10
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Vaccine 0.25 ml Intramuscular
Subject Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular
Comparator Non-adjuvanted Trivalent Influenza Vaccine Vaccine 0.25 ml Intramuscular
Comparator Non-adjuvanted Trivalent Influenza Vaccine Vaccine 0.5 ml Intramuscular
Comparator Quadrivalent influenza vaccine Vaccine 0.25 ml Intramuscular
Comparator Quadrivalent influenza vaccine Vaccine 0.5 ml Intramuscular

Indications